Trial Profile
A Phase 1 Study of AZD6244 in Combination With Cetuximab in Refractory Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Selumetinib (Primary)
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 06 Nov 2012 Planned end date changed from 1 Jan 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 06 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 Oct 2010 New trial record